International journal of dermatology and venereology最新文献

{"title":"Effects of three different biologics on mental health and health-related quality of life in patients with psoriasis: a repeated cross-sectional survey of Chinese patients","authors":"Jie Liu, Xuan Wang, Xiao-Ling Yu, Zhi-Miao Lin, Li-Yan Yuan, Bin Yang","doi":"10.1097/jd9.0000000000000343","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000343","url":null,"abstract":"Objective: Psoriasis is a chronic inflammatory systemic disease that severely impacts patients’ quality of life (QoL) and psychological health. While biologics have been shown to be effective in treating psoriatic lesions, thus improving QoL, real-life data regarding such effects remain scant. We administered a repeated cross-sectional survey to assess the effects of 8 weeks of biologics treatment on the QoL and mental health status of patients with moderate-to-severe plaque psoriasis. Methods: From March to May 2022, patients with moderate-to-severe plaque psoriasis were enrolled and treated with biologics in the outpatient clinic at the Dermatology Hospital of Southern Medical University. Assessments were performed before treatment and after 4 and 8 weeks of treatment with biologics. Psoriasis severity, QoL, and mental health status were evaluated using the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), 36-Item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS). A multivariate generalized estimating equations (GEE) analysis was used to account for repeated measures and to determine the effects of treatment duration and type of biological agent on relevant indicators. Results: Among the 78 enrolled patients, the ranges of pretreatment scores were 4.6–46.8 for the PASI, 1–30 for the DLQI, 31.5–100 for the physical component score (PCS) of the SF-36, 16.6–100 for the mental component score (MCS) of the SF-36, 0–15 for the HADS-A, and 0–17 for the HADS-D. After 8 weeks of biologics treatment, 98.7% (77/78) of patients had obtained PASI 75. All assessed scores changed over time (GEE, P < 0.05). Moreover, there were group-by-time interaction effects for the DLQI score (GEE, P = 0.023) and PCS (GEE, P = 0.029). The HADS-A and HADS-D scores were both decreased at week 8 compared with pretreatment values. Correlation analyses revealed that higher DLQI scores were associated with lower levels of QoL and higher levels of anxiety or depression. Conclusion: Biologics are not only effective in the treatment of skin lesions, but also exert beneficial effects upon the QoL and mental health of patients with psoriasis as determined in the short-term assessments conducted in this study.","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136239510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Stress Affects the Occurrence and Development of Psoriasis Through Neuroendocrine-Immune Regulation: A Narrative Review","authors":"","doi":"10.1097/jd9.0000000000000342","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000342","url":null,"abstract":"This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135715939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy: Erratum.","authors":"","doi":"10.1097/JD9.0000000000000184","DOIUrl":"https://doi.org/10.1097/JD9.0000000000000184","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1097/JD9.0000000000000170.].</p>","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"6 2","pages":"106"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/57/jd9-6-106.PMC10309099.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9800315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Epidemiology of Genital Chlamydial Infection in China in 2019: Erratum.","authors":"","doi":"10.1097/JD9.0000000000000112","DOIUrl":"10.1097/JD9.0000000000000112","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1097/JD9.0000000000000099.].</p>","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"6 2","pages":"86"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/b8/jd9-6-086.PMC10309094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9800313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Nicolau Syndrome Following Metamizole Injection: A Case Report: Erratum.","authors":"","doi":"10.1097/JD9.0000000000000158","DOIUrl":"https://doi.org/10.1097/JD9.0000000000000158","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1097/JD9.0000000000000102.].</p>","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"6 2","pages":"117"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/ca/jd9-6-117.PMC10309092.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9800310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recalcitrant Cutaneous Mastocytosis Treated With Genetically Informed Targeted Therapy: A Case Report.","authors":"Laura Gleason, Volkan Tekmen, Alexa Cohen, Safiyyah Bhatti, Burcu Beksac, Jisun Cha, Pierluigi Porcu, Neda Nikbakht","doi":"10.1097/JD9.0000000000000243","DOIUrl":"10.1097/JD9.0000000000000243","url":null,"abstract":"<p><p>Mastocytosis, a clonal proliferation of mast cells commonly involving the skin and bone marrow, has a varied clinical presentation ranging from cutaneous lesions to systemic disease. Cutaneous mastocytosis is managed symptomatically, but systemic mastocytosis is treated with targeted therapy against the mutated receptor tyrosine kinase c-KIT, the pathogenic driver of mastocytosis. However, there are no guidelines for the treatment of cutaneous mastocytosis refractory to symptomatic management. We herein report a method to select genetically informed therapy for symptomatic and recalcitrant cutaneous mastocytosis.</p><p><strong>Case presentation: </strong>We performed a mutational analysis of dermal mast cells after enrichment by laser capture in a 23-year-old woman with recalcitrant cutaneous mastocytosis. The analysis revealed a aspartic acid to valine substitution at codon 816 (D816V) mutation in the protein c-KIT. Based on these results, we initiated treatment with the multi-kinase/KIT inhibitor midostaurin, a treatment effective against the D816V c-KIT mutation. After 3 months of treatment, the patient exhibited a reduction in the number and size of cutaneous lesions and reported resolution of pruritus and decreased severity of other mast cell-related symptoms.</p><p><strong>Discussion: </strong>The treatment of mastocytosis relies heavily on whether the disease is limited to the skin or systemic. However, there are no guidelines for cutaneous mastocytosis that does not respond to symptomatic management. In the present report describing a patient with recalcitrant cutaneous mastocytosis, we describe a strategy in which skin mutational analysis is used to guide the selection of targeted therapy.</p><p><strong>Conclusion: </strong>Performing mast cell mutational analyses in the skin provides a means to select targeted therapy for symptomatic and refractory cutaneous mastocytosis.</p>","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"6 2","pages":"107-109"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/6a/jd9-6-107.PMC10309087.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9747466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Variants of the GJB6 Gene are Associated with Hearing Loss and Skin Manifestations: A Case Report from Turkey: Erratum","authors":"","doi":"10.1097/jd9.0000000000000308","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000308","url":null,"abstract":"This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135792580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring of Serum TWEAK Level Guides Glucocorticoid Dosages in the Treatment of Systemic Lupus Erythematosus","authors":"Jing-Yun Chen, Yu-Fei Zhang, Yi Wu, Xiao-Kang Wu, Li Wang, Mai Luo, Sheng-Xiang Xiao, Hui-Xia Wang, Yu-Min Xia","doi":"10.1097/jd9.0000000000000294","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000294","url":null,"abstract":"Objective: Accurate assessment of systemic lupus erythematosus (SLE) disease activity is critical. This study explored the relationship between the serum level of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score as well as the role of TWEAK in guiding the glucocorticoid dosage in SLE treatment. Methods: This study involved 131 patients with SLE, 34 with subacute cutaneous lupus erythematosus (SCLE), 22 with discoid lupus erythematosus (DLE), and 32 healthy volunteers. The serum and urinary TWEAK levels were determined. Monomeric C-reactive protein (mCRP), anti-dsDNA IgG, antinuclear antibody (ANA), complements in serum and urinary albumin level were measured. The SLEDAI 2000 (SLEDAI-2K) was used to evaluate disease activity. The correlation of the SLEDAI-2K score with all biomarkers was determined. Methylprednisolone was orally administered to patients with SLE depending on the serum level of TWEAK. Results: TWEAK levels were higher in patients with SLE or SCLE than in patients with DLE or healthy controls. The serum TWEAK level was positively correlated with the SLEDAI-2K score in patients with SLE (P < 0.001), and was more strongly correlated with the SLEDAI-2K score than other parameters (P < 0.001). Moreover, TWEAK-based glucocorticoid therapy was associated with lower SLEDAI-2K scores, better tapering of glucocorticoid doses, and fewer lupus flares in patients with SLE. Conclusions: Serum TWEAK is a useful biomarker reflecting SLE disease activity. Monitoring of the serum TWEAK level can improve the outcomes of glucocorticoid therapy in patients with SLE.","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136334576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgments","authors":"","doi":"10.1097/jd9.0000000000000295","DOIUrl":"https://doi.org/10.1097/jd9.0000000000000295","url":null,"abstract":"","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135288922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biofilm Alterations on the Stepwise Acquisition of Fluconazole-resistant <i>Candida Albicans</i> Isolates.","authors":"Na-Na Song,&nbsp;Guan-Yu Qian,&nbsp;Hai-Lin Zheng,&nbsp;Xiao-Wei Zhou,&nbsp;Huan Mei,&nbsp;Dong-Mei Li,&nbsp;Xiao-Fang Li,&nbsp;Wei-Da Liu","doi":"10.1097/JD9.0000000000000223","DOIUrl":"https://doi.org/10.1097/JD9.0000000000000223","url":null,"abstract":"<p><p>By assessing and comparing the phenotypic changes on the stepwise acquisition of fluconazole resistant <i>Candida albicans</i> isolates, we could find and describe the relationship between drug resistance and biofilm formation ability in a series of clonal strains.</p><p><strong>Methods: </strong>We performed antifungal susceptibility of five drugs (fluconazole, itraconazole, voriconazole, caspofungin and amphotericin B) to further verify the antifungal activity of the six isolates <i>in vitro</i>. Then we combined hyphal formation assay, cell surface hydrophobicity test positively related to adherence ability, and biofilm assays <i>in vitro</i> to observe and compare the phenotypic characteristics of our six clonal strains.</p><p><strong>Results: </strong>Biofilm capability is enhanced for four drug- intermediate strains, whereas the initial susceptible strain and the final resistant strain are both poor in adherence, hyphal growth and biofilm formation.</p><p><strong>Conclusions: </strong>It was suggested that the biofilm formation ability were not absolutely related to the degree of fluconazole resistance.</p>","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"5 3","pages":"132-139"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/e6/jd9-5-132.PMC9521591.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33490490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}